Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP133275.RA2TPFrpHLZD3g3wHmoKbH1orhrHdMvU_TDgcbei6EvA4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP133275.RA2TPFrpHLZD3g3wHmoKbH1orhrHdMvU_TDgcbei6EvA4130_assertion type Assertion NP133275.RA2TPFrpHLZD3g3wHmoKbH1orhrHdMvU_TDgcbei6EvA4130_head.
- NP133275.RA2TPFrpHLZD3g3wHmoKbH1orhrHdMvU_TDgcbei6EvA4130_assertion description "[Recipient MTHFR polymorphisms (C677T) were associated with acute GvHD (P=0.03), and recipient VDR TaqI with TRM and overall survival (P=0.006 and P=0.04, respectively).Genetic factors that interfere with drug metabolisms are associated with treatment-related toxicities, GvHD and survival after HLA-identical HSCT in patients with leukemia and should be investigated prospectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP133275.RA2TPFrpHLZD3g3wHmoKbH1orhrHdMvU_TDgcbei6EvA4130_provenance.
- NP133275.RA2TPFrpHLZD3g3wHmoKbH1orhrHdMvU_TDgcbei6EvA4130_assertion evidence source_evidence_literature NP133275.RA2TPFrpHLZD3g3wHmoKbH1orhrHdMvU_TDgcbei6EvA4130_provenance.
- NP133275.RA2TPFrpHLZD3g3wHmoKbH1orhrHdMvU_TDgcbei6EvA4130_assertion SIO_000772 19005482 NP133275.RA2TPFrpHLZD3g3wHmoKbH1orhrHdMvU_TDgcbei6EvA4130_provenance.
- NP133275.RA2TPFrpHLZD3g3wHmoKbH1orhrHdMvU_TDgcbei6EvA4130_assertion wasDerivedFrom gad-20150221 NP133275.RA2TPFrpHLZD3g3wHmoKbH1orhrHdMvU_TDgcbei6EvA4130_provenance.
- NP133275.RA2TPFrpHLZD3g3wHmoKbH1orhrHdMvU_TDgcbei6EvA4130_assertion wasGeneratedBy ECO_0000203 NP133275.RA2TPFrpHLZD3g3wHmoKbH1orhrHdMvU_TDgcbei6EvA4130_provenance.